SS Innovations International Reports Record Q2 Revenue, Bolstering Case for Affordable Robotic Surgery

SS Innovations International (NASDAQ: SSII) has reported record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year, driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system to 30 units. This growth underscores the company's progress in expanding access to robotic surgery, particularly in underserved markets. The company's gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%, reflecting improved operational efficiency. Although SS Innovations posted a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier, the revenue surge and strategic investments signal a focus on long-term growth.

For the first half of the fiscal year, revenue increased 65.6% to $25 million, with SSi Mantra installations up 47.4% to 56 systems. As of June 30, the company had $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries. The company has also reported 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. Notably, SS Innovations recently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, demonstrating the system's capability to bridge geographic gaps in surgical care.

The company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027. Additionally, SS Innovations believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for the company's expansion into major markets, potentially positioning the SSi Mantra as a cost-effective alternative to established robotic surgery systems.

The implications of these results extend beyond financial performance. SS Innovations' mission to make robotic surgery affordable and accessible aligns with a growing demand for minimally invasive procedures in emerging economies. The company's robust installation growth and telesurgery achievements highlight its potential to democratize advanced surgical technology. As the company awaits regulatory approvals, its strong cash position and lack of debt provide a solid foundation for scaling operations. Investors and healthcare stakeholders will be watching closely as SS Innovations moves toward FDA clearance and CE marking, which could open significant market opportunities.

For more details on the company's performance, visit the full press release at https://ibn.fm/nTMso. Stay updated with the latest news on SS Innovations at https://ibn.fm/SSII.